1. Cancer risk and genotype–phenotype correlation in Japanese patients with Cowden syndrome

   • Satoshi Teramae
   • Naoki Muguruma
   • Tetsuji Takayama

   Original Article 02 February 2022 Pages: 639 - 647

   

2. Male patients with papillary thyroid cancer have a higher risk of extranodal extension

   • Hu Hei
   • Bin Zhou
   • Jianwu Qin

   Original Article 08 January 2022 Pages: 648 - 654

   

3. Prognostic laboratory score to predict 14-day mortality in terminally ill patients with respiratory malignancy

   • Mari Tanaka
   • Natsuko Kawai
   • Norihiro Yuasa

   Original Article 23 January 2022 Pages: 655 - 664

   

4. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050

   • Rajesh Sharma

   Original Article 12 January 2022 Pages: 665 - 675

   

5. Phase II study of carboplatin–paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024

   • Satoshi Oizumi
   • Kei Takamura
   • North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group

   Original Article 29 January 2022 Pages: 676 - 683

   

6. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

   • Akio Nakasya
   • Yuya Hagiwara
   • Ichinosuke Hyodo

   Original Article Open access 28 January 2022 Pages: 684 - 694

   

7. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

   • Thomas John
   • Hiroshi Sakai
   • Shun Lu

   Original Article Open access 19 February 2022 Pages: 695 - 706

   

8. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study

   • Yiqun Han
   • Yun Wu
   • Binghe Xu

   Original Article Open access 18 January 2022 Pages: 707 - 716

   

9. Novel combined fibrosis-based index predicts the long-term outcomes of hepatocellular carcinoma after hepatic resection

   • Mitsuru Yanagaki
   • Yoshihiro Shirai
   • Toru Ikegami

   Original Article 11 January 2022 Pages: 717 - 728

   

10. Relationship between psoas muscle index and long-term survival in older patients aged ≥ 80 years after endoscopic submucosal dissection for gastric cancer

    • Nobuhito Ito
    • Kohei Funasaka
    • Mitsuhiro Fujishiro

    Original Article 11 January 2022 Pages: 729 - 738

    

11. Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade

    • Chih-Chieh Ko
    • Shu-Yein Ho
    • Teh-Ia Huo

    Original Article 04 February 2022 Pages: 739 - 748

    

12. Clinicopathological and molecular characteristics of early-onset vs late-onset colorectal cancer according to tumor location

    • Yongle Chen
    • Zexian Chen
    • Xiaosheng He

    Original Article 26 January 2022 Pages: 749 - 755

    

13. Proposal for a tumor budding predictive score derived from endoscopic biopsy samples in colorectal cancer

    • Masato Yamadera
    • Eiji Shinto
    • Hideki Ueno

    Original Article 29 January 2022 Pages: 756 - 764

    

14. Hormone replacement therapy in relation to the risk of colorectal cancer in women by BMI: a multicentre study with propensity score matching

    • Lingkai Xu
    • Lin Li
    • Xiaochen Shu

    Original Article 13 January 2022 Pages: 765 - 773

15. Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers

    • Takeshi Ujike
    • Motohide Uemura
    • Norio Nonomura

    Original Article Open access 04 February 2022 Pages: 774 - 780

    

16. Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy

    • Shuichi Morizane
    • Masashi Honda
    • Atsushi Takenaka

    Original Article 25 January 2022 Pages: 781 - 789

    

17. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer

    • Hiroki Nasu
    • Shin Nishio
    • Kimio Ushijima

    Original Article 05 January 2022 Pages: 790 - 801

    

18. Role of adjuvant chemotherapy in patients with localized, undifferentiated pleomorphic sarcoma of soft tissue: a population-based cohort study

    • Hiroshi Kobayashi
    • Liuzhe Zhang
    • Sakae Tanaka

    Original Article 22 January 2022 Pages: 802 - 810

    

19. CircRNA PVT1 promotes proliferation and chemoresistance of osteosarcoma cells via the miR-24-3p/KLF8 axis

    • Bin Wang
    • Lifang Yan
    • Weiguo Liang

    Original Article 16 February 2022 Pages: 811 - 822

    

20. Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)

    • Yukari Tsubata
    • Kana Watanabe
    • Takeshi Isobe

    Correction 08 March 2022 Pages: 823 - 824

21. Correction to: Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases

    • Masanori Ono
    • Kimikazu Matsumoto
    • Nao Suzuki

    Correction Open access 21 February 2022 Pages: 825 - 826

22. Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

    • Yoichiro Tohi
    • Takuma Kato
    • Mikio Sugimoto

    Correction 03 March 2022 Pages: 827 - 827